Relias Media - Continuing Medical Education Publishing

The trusted source for

healthcare information and

CONTINUING EDUCATION.

  • Sign In
  • Sign Out
  • MyAHC
    • Home
      • Home
      • Newsletters
      • Blogs
      • Archives
      • CME/CE Map
      • Shop
    • Emergency
      • All Products
      • Publications
      • Study Guides
      • Webinars
      • Group Sales
    • Hospital
      • All Products
      • Publications
      • Study Guides
      • Webinars
      • Group Sales
    • Clinical
      • All Products
      • Publications
      • Study Guides
      • Webinars
      • Group Sales
    • All Access
      • My Subscription
      • Subscribe Now
    • My Account
      • My Subscriptions
      • My Content
      • My Orders
      • My CME/CE
      • My Transcript
    Home » Tenecteplase vs. Alteplase for Thrombolysis in Basilar Artery Occlusion
    STROKE ALERT

    Tenecteplase vs. Alteplase for Thrombolysis in Basilar Artery Occlusion

    April 1, 2021
    No Comments
    Reprints
    Facebook Twitter Linkedin Share Share

    Related Articles

    Tenecteplase vs. Alteplase for Ischemic Stroke

    Endovascular Treatment for Acute Basilar Artery Occlusion Is Safe and Effective

    Basilar Artery Occlusion: Endovascular Thrombectomy and Medical Therapy Have Similar Outcomes

    Related Products

    Alzheimer’s Disease: What the Primary Care Physician Needs to Know

    All Access Subscription: Online

    Keywords

    artery

    therapy

    basilar

    alteplase

    occlusion

    tenecteplase

    By Matthew E. Fink, MD

    Louis and Gertrude Feil Professor and Chair, Department of Neurology, Associate Dean for Clinical Affairs, New York Presbyterian/Weill Cornell Medical College

    SOURCE: Alemseged F, Ng FC, Williams C, et al. Tenecteplase vs alteplase before endovascular therapy in basilar artery occlusion. Neurology 2021;96:e1272-e1277.

    Basilar artery occlusion is a dangerous clinical syndrome of large artery occlusion that carries a high morbidity and mortality with severe disability in survivors. In multiple trials, alteplase has shown minimal benefit in achieving reperfusion in patients with large artery occlusion, including the basilar artery. Tenecteplase is a modified variant of alteplase that has greater specificity in binding to fibrin, a longer half-life, and can be administered in a single bolus. This makes it operationally easier to use and theoretically more effective.

    In the head-to-head trial of tenecteplase vs. alteplase before endovascular therapy in ischemic stroke (EXTEND-IA-TNK), tenecteplase led to a higher rate of reperfusion and improved clinical outcomes compared with alteplase.1 To assess the benefit in patients with basilar artery occlusion, the authors retrospectively analyzed all of the cases of basilar artery occlusion reported in several studies that compared the use of tenecteplase with alteplase. A total of 110 patients with basilar artery occlusion were included and were treated with either alteplase or tenecteplase for intravenous thrombolysis prior to endovascular therapy. Nineteen patients were treated with tenecteplase and 91 with alteplase. Reperfusion > 50% was successful in 26% of patients treated with tenecteplase vs. 7% of patients treated with alteplase, despite shorter thrombolysis-to-arterial puncture times in the tenecteplase-treated group. The groups were not matched and they were unequal, but the risk ratio for alteplase was 4.0, P = 0.02. There was no difference in symptomatic intracranial hemorrhage between the groups. This observational study suggests benefits with tenecteplase above alteplase, and it warrants additional randomized trials of this agent in basilar artery occlusion, as well as other types of large vessel occlusions.

    REFERENCE

    1. Campbell BC, Mitchell PJ, Churilov L, et al. Tenecteplase versus alteplase before thrombectomy for ischemic stroke. N Engl J Med 2018;378:1573-1582.

    Post a comment to this article

    Report Abusive Comment

    www.reliasmedia.com

    Neurology Alert

    View PDF
    Neurology Alert (Vol. 40, No. 8) - April 2021
    April 1, 2021

    Table Of Contents

    Phospho-Tau217 Blood Biomarker May Help to Diagnose Early Alzheimer’s Disease

    Cognitive Deficits in Patients Recovering from COVID-19

    Polyradiculoneuropathy from Immune Checkpoint Inhibitors

    Brain Cancer and Brain Injury Drive Systemic Immunosuppression

    Tenecteplase vs. Alteplase for Thrombolysis in Basilar Artery Occlusion

    Tranexamic Acid in Patients with Intracerebral Hemorrhage Does Not Improve Outcomes

    Atorvastatin and Low-Dose Dexamethasone for Treatment of Chronic Subdural Hematoma

    Begin Test

    Buy this Issue/Course

    Financial Disclosure: Dr. Isaacson (author) reports he is a consultant for Genentech/Roche and Biogen, Dr. Rubin (author) reports he is a consultant for Merck Sharpe & Dohme Corp., and Dr. Noch (author) reports he is a stockholder in Destroke, Inc. All of the relevant financial relationships listed for these individuals have been mitigated. None of the remaining authors or planners for this educational activity have relevant financial relationships to disclose with ineligible companies whose primary business is producing, marketing, selling, re-selling, or distributing healthcare products used by or on patients.

    Shop Now: Search Products

    • Subscription Publications
    • Books & Study Guides
    • Webinars
    • Group & Site
      Licenses
    • State CME/CE
      Requirements

    Webinars And Events

    View All Events
    • Home
      • Home
      • Newsletters
      • Blogs
      • Archives
      • CME/CE Map
      • Shop
    • Emergency
      • All Products
      • Publications
      • Study Guides
      • Webinars
      • Group Sales
    • Hospital
      • All Products
      • Publications
      • Study Guides
      • Webinars
      • Group Sales
    • Clinical
      • All Products
      • Publications
      • Study Guides
      • Webinars
      • Group Sales
    • All Access
      • My Subscription
      • Subscribe Now
    • My Account
      • My Subscriptions
      • My Content
      • My Orders
      • My CME/CE
      • My Transcript
    • Help
    • Search
    • About Us
    • Sign In
    • Register
    Relias Media - Continuing Medical Education Publishing

    The trusted source for

    healthcare information and

    CONTINUING EDUCATION.

    Customer Service

    customerservice@reliasmedia.com

    U.S. and Canada: 1-800-688-2421 x 2

    International +1-404-262-5476 x 2

    Accounts Receivable

    1-800-688-2421 x 3
    ReliasMedia_AR@reliasmedia.com

    Sales

    1-800-688-2421 x 1

    Mailing Address

    • 1010 Sync St., Suite 100
      Morrisville, NC 27560-5468
      USA

    © 2022 Relias. All rights reserved.

    Do Not Sell My Personal Information  Privacy Policy  Terms of Use  Contact Us  Reprints  Group Sales

    For DSR inquiries or complaints, please reach out to Wes Vaux, Data Privacy Officer, DPO@relias.com

    Design, CMS, Hosting & Web Development :: ePublishing